Maina joined Sofinnova Partners in January 2018. Maina has a long track record as a successful healthcare investor. Prior to Sofinnova, Maina was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London since 2006. Maina has led or co-led numerous investments and sat on the Board of a number of UK biotech companies, such as Autifony, Cellmedica, Psioxus Therapeutics, Pulmocide, Topivert Pharma, Puridify (sold to GE), Thiakis (sold to Wyeth) and Respivert (sold to J&J). Previously, Maina worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Maina has received strong professional and institutional recognition and was named one of UK’s Top women in Biopharma several years in a row. Maina has a BSc from the University of Texas at Austin (United States) and an MBA from the Imperial Business School in London (United Kingdom).